---
title: "Journey Medical | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 15.96 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286310434.md"
datetime: "2026-05-13T20:13:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286310434.md)
  - [en](https://longbridge.com/en/news/286310434.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286310434.md)
---

# Journey Medical | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 15.96 M

Revenue: As of FY2026 Q1, the actual value is USD 15.96 M, beating the estimate of USD 15.48 M.

EPS: As of FY2026 Q1, the actual value is USD -0.08.

EBIT: As of FY2026 Q1, the actual value is USD -443 K.

### Segment Revenue

#### Emrosi® Revenues

-   Emrosi® revenues were $6.3 million for the first quarter ended March 31, 2026, compared to $2.1 million for the same period in 2025.

#### Product Revenue, Net

-   Product revenue, net, was $15,921 thousand for the three-month period ended March 31, 2026, compared to $13,139 thousand for the same period in 2025.

#### Other Revenue

-   Other revenue was $40 thousand for the three-month period ended March 31, 2026, compared to $0 for the same period in 2025.

### Operational Metrics

#### Gross Margin

-   Gross margin decreased to 61.0% for the first quarter of 2026, from 63.5% in the first quarter of 2025, primarily due to a - $1.3 million non-recurring non-cash charge against cost of goods associated with a write-down of API inventory.

#### Selling, General and Administrative Expenses

-   Selling, general and administrative expenses decreased by - $0.5 million to $10.1 million for the three-month period ended March 31, 2026, from $10.6 million for the prior year quarter, mainly due to lower Emrosi® launch costs.

#### Net Loss

-   Net loss for Journey Medical Corporation narrowed to - $2.2 million, or - $0.08 per share basic and diluted, for the first quarter of 2026, compared to a net loss of - $4.1 million, or - $0.18 per share basic and diluted, for the first quarter of 2025.

#### Loss from Operations

-   Loss from operations was - $1,492 thousand for the three-month period ended March 31, 2026, compared to - $3,324 thousand for the same period in 2025.

#### Non-GAAP Adjusted EBITDA

-   Non-GAAP Adjusted EBITDA was positive $0.6 million, or $0.02 per share basic and diluted, for the first quarter of 2026, compared to negative - $0.9 million, or - $0.04 loss per share basic diluted, for the first quarter of 2025.

#### Cost of Goods Sold (excluding amortization of acquired intangible assets)

-   Cost of goods sold (excluding amortization of acquired intangible assets) was $6,218 thousand for Q1 2026, up from $4,790 thousand for Q1 2025.

#### Amortization of Acquired Intangible Assets

-   Amortization of acquired intangible assets was $1,126 thousand for Q1 2026, compared to $1,065 thousand for Q1 2025.

#### Research and Development Expenses

-   Research and development expenses were $0 for Q1 2026, compared to $39 thousand for Q1 2025.

### Cash Position

-   Cash and cash equivalents increased to $27.2 million at March 31, 2026, compared to $24.1 million at December 31, 2025.

### Unique Metrics / Operational Highlights

#### Emrosi® Prescriptions

-   Emrosi® prescriptions totaled 29,968 for the first quarter of 2026, an increase from 27,023 in the fourth quarter of 2025.

#### Group Purchasing Organization (GPO) Contract

-   Journey Medical Corporation secured a contract with the third largest Group Purchasing Organization (GPO) in the United States for Emrosi® on April 21, 2026, expanding access to approximately 85% of all commercial lives in the nation.

### Outlook / Guidance

-   Journey Medical Corporation expects continued improvement in operating leverage, driven by net product sales growth and disciplined investment. The company anticipates that expanded payer access for Emrosi® will facilitate further growth in prescription demand. Journey Medical Corporation believes it is well-positioned to execute its strategy and deliver strong financial progress throughout the year, supported by its cash position and Emrosi®’s market performance.

### Related Stocks

- [DERM.US](https://longbridge.com/en/quote/DERM.US.md)

## Related News & Research

- [Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference | DERM Stock News](https://longbridge.com/en/news/286965311.md)
- [ABN Amro Investment Solutions Trims Stock Position in Deere & Company $DE](https://longbridge.com/en/news/287174114.md)
- [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md)
- [ABN Amro Investment Solutions Reduces Holdings in The Sherwin-Williams Company $SHW](https://longbridge.com/en/news/287174176.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)